Glucocorticoids remain the most commonly used anti-inflammatory drugs in dermatology, however, their use is limited by the development of side effects, particularly skin atrophy. We discovered that REDD1 is causatively involved in skin atrophy. The proposed studies will test the novel concept of safe anti-inflammatory therapy in which glucocorticoids are combined with REDD1 inhibitors.
|Effective start/end date||3/22/17 → 2/29/24|
- National Institute of Allergy and Infectious Diseases (5R01AI125366-05)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.